Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 311

1.

Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.

Karakukcu C, Karakukcu M, Unal E, Patiroglu T, Ozdemir MA, Torun YA, Tang PH.

Hemoglobin. 2012;36(3):219-29. doi: 10.3109/03630269.2012.672507. Epub 2012 Apr 6.

PMID:
22483337
2.

Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major.

Forni GL, Podestà M, Musso M, Piaggio G, Musallam KM, Balocco M, Pozzi S, Rosa A, Frassoni F.

Haematologica. 2013 Apr;98(4):555-9. doi: 10.3324/haematol.2012.076240. Epub 2012 Dec 14.

3.

A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.

Ha SY, Mok AS, Chu WC, Raskalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC.

Hemoglobin. 2009;33(5):323-31. doi: 10.3109/03630260903211979.

PMID:
19814678
4.

Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.

Pantalone GR, Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Romeo MA, Magnano C, Caruso V, Argento C, Gerardi C, Campisi S, Violi P, Malizia R, Cianciulli P, Rizzo M, D'Ascola DG, Quota A, Prossomariti L, Fidone C, Rigano P, Pepe A, D'Amico G, Morabito A, Gluud C.

Hemoglobin. 2011;35(3):206-16. doi: 10.3109/03630269.2011.570674.

PMID:
21599433
5.

Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.

Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M.

Acta Haematol. 2010;123(3):148-52. doi: 10.1159/000287238. Epub 2010 Feb 24.

PMID:
20185899
6.

Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.

Hatzipantelis ES, Karasmanis K, Perifanis V, Vlachaki E, Tziomalos K, Economou M.

Hemoglobin. 2014;38(2):111-4. doi: 10.3109/03630269.2013.867407. Epub 2013 Dec 18.

PMID:
24351163
7.

The effects of chelators on zinc levels in patients with thalassemia major.

Erdoğan E, Canatan D, Ormeci AR, Vural H, Aylak F.

J Trace Elem Med Biol. 2013 Apr;27(2):109-11. doi: 10.1016/j.jtemb.2012.10.002. Epub 2012 Nov 16.

PMID:
23164519
9.

Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.

Tsironi M, Assimakopoulos G, Polonofi K, Rigaki K, Aessopos A.

Hemoglobin. 2008;32(1-2):29-34. doi: 10.1080/03630260701680474.

PMID:
18274980
10.

Update on thalassemia treatment in Taiwan, including bone marrow transplantation, chelation therapy, and cardiomyopathy treatment effects.

Peng CT, Chang JS, Wang LY, Chiou SS, Hsiao CC, Wang SC, Hung GY, Wu KH.

Hemoglobin. 2009;33(5):304-11. doi: 10.3109/03630260903212969.

PMID:
19814676
11.

Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.

Hagag AA, Hamam MA, Taha OA, Hazaa SM.

Infect Disord Drug Targets. 2015;15(2):98-105.

PMID:
26205801
12.

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

Cappellini MD, Bejaoui M, Agaoglu L, Canatan D, Capra M, Cohen A, Drelichman G, Economou M, Fattoum S, Kattamis A, Kilinc Y, Perrotta S, Piga A, Porter JB, Griffel L, Dong V, Clark J, Aydinok Y.

Blood. 2011 Jul 28;118(4):884-93. doi: 10.1182/blood-2010-11-316646. Epub 2011 May 31. Erratum in: Blood. 2011 Nov 3;118(18):5060.

13.

Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*.

Ha SY, Mok AS, Chu WC, Rasalkar DD, Cheuk DK, Chiang AK, Ho MH, Chan GC.

Hemoglobin. 2011;35(3):199-205. doi: 10.3109/03630269.2011.579007.

PMID:
21599432
14.

Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.

McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T.

Health Technol Assess. 2009 Jan;13(1):iii-iv, ix-xi, 1-121. doi: 10.3310/hta13010. Review.

16.

The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.

Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.

Pediatr Blood Cancer. 2015 Sep;62(9):1592-6. doi: 10.1002/pbc.25533. Epub 2015 Mar 28.

PMID:
25820920
17.

Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.

Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.

Hemoglobin. 2014;38(5):345-50. doi: 10.3109/03630269.2014.940462. Epub 2014 Jul 22.

PMID:
25051423
18.

Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.

Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P.

Blood Cells Mol Dis. 2009 May-Jun;42(3):247-51. doi: 10.1016/j.bcmd.2009.01.002. Epub 2009 Feb 23.

PMID:
19233692
19.

Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.

Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ.

Hemoglobin. 2008;32(1-2):41-7. doi: 10.1080/03630260701727085.

PMID:
18274982
20.

Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy.

Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S.

Blood. 1996 Jul 15;88(2):705-13.

Supplemental Content

Support Center